Eli Lilly shares slid 8.2% last month thanks to tariff tremors and Medicare’s snub of pricey weight-loss drugs. The company’s ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

The day-to-day volatility for the S&P 500 settled down on Monday and Tuesday. But two-thirds of stocks in the U.S. large-cap benchmark index have declined this year, with 220 of the 500 stocks down at ...

VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...

The day-to-day volatility for the S&P 500 settled down on Monday and Tuesday. But two-thirds of stocks in the U.S. large-cap benchmark index have declined this year, with 220 of the 500 stocks down at ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

The market is characterized by trends such as personalized medicine, targeted therapies, and combination treatments. Key players include Eli Lilly, B ...

The 7MM soft tissue sarcoma (STS) market is estimated to reach USD 6,465.7 million by 2030 from USD 2,943.3 million in 2019 at a CAGR of 7.4%.

Employment in the U.S. life sciences sector hit a record high in 2024, and more job growth is expected in 2025.

In the most recent trading session, Eli Lilly (LLY) closed at $757.18, indicating a +0.38% shift from the previous trading day.